Two-year outcomes of treatment-experienced adults after programmatic transitioning to dolutegravir: longitudinal data from the VICONEL HIV cohort in Lesotho.
Nadine TschumiMalebanye LerotholiLipontso MotaboliMoliehi MoketeNiklaus Daniel LabhardtJennifer A BrownPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023)
In the VICONEL HIV cohort in Lesotho, 14'242 adults transitioned from efavirenz- or nevirapine- to dolutegravir-based antiretroviral therapy by October 2021. Viral suppression <50 copies/mL was 84.8%, 93.9%, and 95.4% pre-, 12 months post-, and 24 months post-transition. Sex, age, pre-transition viral load, and treatment backbone correlated with 24-month viremia.